文献速递糖尿病

肝靶向餐时胰岛素的降糖效应差异:1型糖尿病6个月2b期研究

Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2019-09-24

ISLE-1为26周2b期随机双盲非劣效试验,比较HDV-赖脯胰岛素与赖脯胰岛素在176例1型糖尿病中的效果。A1C变化差异为0.09%(95%CI -0.18%至0.35%),证实非劣效。基线A1C显著修饰低血糖风险:A1C≥8.5%者HDV-L严重低血糖发生率更低(69 vs 97事件/100人年,P=0.03),而A1C<8.5%者HDV-L低血糖风险更高(191 vs 21事件/100人年,P=0.001)。

要点

  • HDV-L在1型糖尿病中A1C非劣效于赖脯胰岛素,差异0.09%(95%CI -0.18%至0.35%)。
  • 基线A1C≥8.5%者HDV-L严重低血糖发生率更低(69 vs 97事件/100人年,P=0.03)。
  • 基线A1C<8.5%者HDV-L严重低血糖发生率更高(191 vs 21事件/100人年,P=0.001)。

核心结论

  • HDV-L的肝脏生物分布可能增强1型糖尿病中的胰岛素效应,低血糖结局因基线A1C不同而呈现分歧。

研究设计与样本

  • ISLE-1为26周、2b期、多中心、随机、双盲、非劣效试验,纳入176例1型糖尿病患者(HDV-L组118例,LIS组58例)。

主要发现

  • A1C自基线变化差异为0.09%(95%CI -0.18%至0.35%),证实非劣效(预设界值≤0.4%)。
  • 总体低血糖或胰岛素剂量无统计学显著差异,但基线A1C修饰治疗组对严重低血糖的效应(交互P<0.001)。
  • A1C≥8.5%者HDV-L与LIS严重低血糖发生率分别为69和97事件/100人年(P=0.03)。
  • A1C<8.5%者HDV-L与LIS严重低血糖发生率分别为191和21事件/100人年(P=0.001)。
  • A1C≥8.5%者HDV-L终点餐时胰岛素剂量约低25%(P=0.02),A1C结局相似。

关键数值与推荐

  • 非劣效界值为A1C变化差异≤0.4%。
  • 基线A1C≥8.5%时HDV-L严重低血糖发生率69事件/100人年,LIS为97事件/100人年(P=0.03)。
  • 基线A1C<8.5%时HDV-L严重低血糖发生率191事件/100人年,LIS为21事件/100人年(P=0.001)。
  • 基线A1C≥8.5%者HDV-L终点餐时胰岛素剂量较LIS低约25%(P=0.02)。

临床怎么用

  • 对于基线A1C≥8.5%的1型糖尿病患者,HDV-L可能减少严重低血糖并降低餐时胰岛素剂量。
  • 对于基线A1C<8.5%的患者,使用HDV-L需警惕严重低血糖风险增加。
  • HDV-L的A1C降糖效果与赖脯胰岛素非劣效,但低血糖风险因基线A1C而异,需个体化选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hepatic-directed vesicle insulin (HDV) uses a hepatocyte-targeting moiety passively attaching free insulin, improving subcutaneous insulin's hepatic biodistribution. We assessed HDV-insulin lispro (HDV-L) versus insulin lispro (LIS) in type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: Insulin Liver Effect (ISLE-1) was a 26-week, phase 2b, multicenter, randomized, double-blind, noninferiority trial. RESULTS: Among 176 randomized participants (HDV-L n = 118, LIS n = 58), the difference in change from baseline A1C was 0.09% (95% CI -0.18% to 0.35%), confirming noninferiority (prespecified margin ≤0.4%). Overall, there were no statistically significant differences between treatments for hypoglycemia or insulin dosing. However, baseline A1C modified the treatment group effect (interaction P < 0.001) on clinically apparent hypoglycemia designated by treatment-blinded investigators as severe. Thus, at higher baseline A1C, there was less hypoglycemia and lower insulin dosing with similar A1C outcomes during HDV-L versus LIS, whereas greater risk of hypoglycemia despite similar A1C outcomes and insulin doses was observed with lower baseline A1C. Among poorly controlled participants (A1C ≥8.5%), incidence rates of severe hypoglycemia in the HDV-L and LIS arms were 69 and 97 events/100 person-years, respectively (P = 0.03), whereas with A1C <8.5%, respective rates were 191 and 21 events/100 person-years (P = 0.001). Similar A1C-dependent trends in hypoglycemia were seen with continuous glucose monitoring. Among poorly controlled participants, bolus insulin doses at end point were ∼25% lower with HDV-L (P = 0.02), despite similar A1C outcomes; in better-controlled participants, insulin doses and A1Cs were stable over time in both subgroups. No safety signals were identified. CONCLUSIONS: Hepatic biodistribution of HDV-L appears to potentiate insulin effect in T1D, with divergent clinical outcomes in hypoglycemia dependent on baseline A1C.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Klonoff D, Bode B, Cohen N, et al. Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes. Diabetes Care. 2019. PMID: 31551249. doi:10.2337/dc19-0152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。